Mariem Charafeddine

Survival and Complications of Beta-Thalassemia in Lebanon

Khalil M. Charafeddine, Hussain Isma’eel, Mariem Charafeddine et al. · Acta Haematologica · 2008 · 30 citations

Chelation Therapy, Ferritin Level, Heart Failure +11

Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials

Darshan Mehta, E. Cohen, Mariem Charafeddine et al. · Infectious Diseases and Therapy · 2017 · 30 citations · Full text

High-Dose Pegylated Interferon-α and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial)

Stéphane Chevaliez, Christophe Hézode, Alexandre Soulier et al. · Gastroenterology · 2011 · 27 citations · Full text

High-dose Pegylated Interferon-α, Hepatology, Hepatitis C +12

Efficacy and safety results of patients with <scp>HCV</scp> genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (<scp>QUARTZ II</scp>‐<scp>III</scp>)

Stephen D. Shafran, Douglas W. Shaw, Mariem Charafeddine et al. · Journal of Viral Hepatitis · 2017 · 14 citations

Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries

Péter Ferenci, Stefan Bourgeois, Peter Buggisch et al. · Journal of Viral Hepatitis · 2019 · 14 citations · Full text